Literature DB >> 12893686

Absence of p53 leads to accelerated neointimal hyperplasia after vascular injury.

Masataka Sata1, Kimie Tanaka, Nobukazu Ishizaka, Yasunobu Hirata, Ryozo Nagai.   

Abstract

OBJECTIVE: It has been suggested that deregulated expression of the tumor suppressor protein p53 may play a role in the pathogenesis of occlusive vascular remodeling. However, the role of p53 in cell proliferation and apoptosis in vascular lesions has been controversial. METHODS AND
RESULTS: We tested the potential involvement of p53-mediated molecular signaling in lesion formation using a mouse model of vascular injury that may resemble balloon angioplasty. A large wire was inserted into the femoral artery of p53+/+ and p53-/- mice. There was no significant difference in the occurrence of rapid-onset apoptosis, that is, 4 hours after injury. At 2 weeks, the number of proliferating cells in the lesion of p53-/- mice was significantly higher than that observed in p53+/+ mice. The frequency of apoptotic cells was significantly lower in p53-/- mice than in p53+/+ mice. At 4 weeks, the neointimal hyperplasia of p53-/- mice was greater than that of p53+/+ mice. There was no significant difference in the frequency of apoptosis in the lesions.
CONCLUSIONS: These results indicate a crucial role of p53 in pathological vascular remodeling after mechanical injury and provide the basis for the development of new therapies targeting p53 for a prophylactic treatment of vascular diseases.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12893686     DOI: 10.1161/01.ATV.0000089327.48154.32

Source DB:  PubMed          Journal:  Arterioscler Thromb Vasc Biol        ISSN: 1079-5642            Impact factor:   8.311


  6 in total

1.  Inhibition of neddylation by MLN4924 improves neointimal hyperplasia and promotes apoptosis of vascular smooth muscle cells through p53 and p62.

Authors:  Tang-Jun Ai; Jian-Yong Sun; Lin-Juan Du; Chaoji Shi; Chao Li; Xue-Nan Sun; Yan Liu; Lihui Li; Zhixiong Xia; Lijun Jia; Jianmiao Liu; Sheng-Zhong Duan
Journal:  Cell Death Differ       Date:  2017-10-13       Impact factor: 15.828

2.  Myeloid p53 regulates macrophage polarization and venous thrombus resolution by inflammatory vascular remodeling in mice.

Authors:  Subhradip Mukhopadhyay; Toni M Antalis; Khanh P Nguyen; Mark H Hoofnagle; Rajabrata Sarkar
Journal:  Blood       Date:  2017-03-20       Impact factor: 22.113

3.  Inhibition of Smooth Muscle β-Catenin Hinders Neointima Formation After Vascular Injury.

Authors:  Dario F Riascos-Bernal; Prameladevi Chinnasamy; Jordana N Gross; Vanessa Almonte; Lander Egaña-Gorroño; Dippal Parikh; Smitha Jayakumar; Liang Guo; Nicholas E S Sibinga
Journal:  Arterioscler Thromb Vasc Biol       Date:  2017-03-16       Impact factor: 8.311

4.  Kruppel-like factor 5 shows proliferation-specific roles in vascular remodeling, direct stimulation of cell growth, and inhibition of apoptosis.

Authors:  Toru Suzuki; Daigo Sawaki; Kenichi Aizawa; Yoshiko Munemasa; Takayoshi Matsumura; Junichi Ishida; Ryozo Nagai
Journal:  J Biol Chem       Date:  2009-02-03       Impact factor: 5.157

5.  Epac1 is upregulated during neointima formation and promotes vascular smooth muscle cell migration.

Authors:  Utako Yokoyama; Susumu Minamisawa; Hong Quan; Toru Akaike; Meihua Jin; Koji Otsu; Coskun Ulucan; Xu Wang; Erdenechimeg Baljinnyam; Minoru Takaoka; Masataka Sata; Yoshihiro Ishikawa
Journal:  Am J Physiol Heart Circ Physiol       Date:  2008-08-08       Impact factor: 4.733

6.  Strain-dependent embryonic lethality and exaggerated vascular remodeling in heparin cofactor II-deficient mice.

Authors:  Ken-ichi Aihara; Hiroyuki Azuma; Masashi Akaike; Yasumasa Ikeda; Masataka Sata; Nobuyuki Takamori; Shusuke Yagi; Takashi Iwase; Yuka Sumitomo; Hirotaka Kawano; Takashi Yamada; Toru Fukuda; Takahiro Matsumoto; Keisuke Sekine; Takashi Sato; Yuko Nakamichi; Yoko Yamamoto; Kimihiro Yoshimura; Tomoyuki Watanabe; Takashi Nakamura; Akimasa Oomizu; Minoru Tsukada; Hideki Hayashi; Toshiki Sudo; Shigeaki Kato; Toshio Matsumoto
Journal:  J Clin Invest       Date:  2007-06       Impact factor: 14.808

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.